Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638808 | 0.89 | TAAR1 (0.39) | TAAR1KMT2ATDP1HSP90AA1SMN1; SMN2 | |
| SCHEMBL638583 | 0.88 | MGLL (0.39) | TAAR1KMT2ATDP1BCHELIPE | |
| SCHEMBL637521 | 0.86 | ELANE (0.40) | TAAR1KMT2ATDP1HSP90AA1LMNA | |
| SCHEMBL636937 | 0.85 | TAAR1 (0.43) | TAAR1KMT2ATDP1HSP90AA1MEN1 | |
| SCHEMBL636819 | 0.82 | EPHX2 (0.35) | TAAR1KMT2ATDP1SMN1; SMN2EPHX2 | |
| SCHEMBL2231640 | 0.82 | TAAR1 (0.44) | TAAR1KMT2ATDP1HSP90AA1SMN1; SMN2 | |
| SCHEMBL916227 | 0.81 | EPHX2 (0.36) | TAAR1KMT2ATDP1SMN1; SMN2EPHX2 | |
| SCHEMBL637631 | 0.81 | MGLL (0.38) | TAAR1KMT2ATDP1MEN1LMNA | |
| SCHEMBL637967 | 0.81 | MGLL (0.38) | TAAR1KMT2ATDP1MEN1LMNA | |
| SCHEMBL636954 | 0.81 | MGLL (0.38) | TAAR1KMT2ATDP1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | TAAR1 1740/4885KMT2A 2442/4885TDP1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.